Here are three products named “Breakthrough Devices” by the FDA since May 1:
1. Optina Diagnostics’ retinal imaging platform uses AI to detect biomarkers of Alzheimer’s disease and other neurodegenerative diseases in eye scans.
2. The KidneyIntelX from Renalytix AI relies on machine learning algorithms to diagnose and manage fast-progressing kidney disease in Type 2 diabetes patients.
3. Grail’s methylation sequencing blood test uses DNA sequencing technology and machine learning algorithms to detect multiple forms of cancer and their tissues of origin.
More articles about AI:
Deep learning system detects ACL tears as accurately as trained radiologists
NIH gives biotech company $300K to use AI to develop hantavirus antibodies
FDA approves AI that detects collapsed lungs in chest X-rays
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
